Premium
Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients
Author(s) -
Silvennoinen Raija,
Kairisto Veli,
Pelliniemi TarjaTerttu,
Putkonen Mervi,
Anttila Pekka,
Säily Marjaana,
Sikiö Anu,
Opas Jorma,
Penttilä Karri,
Kuittinen Taru,
Honkanen Tuomo,
Lundán Tuija,
Juvonen Vesa,
Luukkaala Tiina,
Remes Kari
Publication year - 2013
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12139
Subject(s) - medicine , multiple myeloma , autologous stem cell transplantation , minimal residual disease , bortezomib , oncology , transplantation , dexamethasone , confidence interval , surrogate endpoint , gastroenterology , surgery , bone marrow